SCHEMBL24469867

SCHEMBL24469867

CNC(=O)c1ccc(-n2c(=O)c3c(n4ncc(Cc5ccccc5)c24)CNC(C)C3)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 3/20 0.36
LMNA P02545 2/20 0.35
MAPT P10636 1/20 0.35
OPRM1 P35372 2/20 0.33
OPRD1 P41143 1/20 0.33
MAPK11 Q15759 1/20 0.33
MAPK14 Q16539 1/20 0.33
BRD4 O60885 3/20 0.32
BRD2 P25440 1/20 0.32
BRD3 Q15059 1/20 0.32
BRDT Q58F21 1/20 0.32
OPRL1 P41146 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
TSHR P16473 1/20 0.31
CASP1 P29466 1/20 0.31
ALDH1A1 P00352 2/20 0.31
PKM P14618 1/20 0.31
USP7 Q93009 1/20 0.31
MT-CO1 P00395 1/20 0.31
MT-CO2 P00403 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24469997 0.90 CRBN (0.35) CRBNLMNAMAPTOPRM1OPRD1
SCHEMBL24469950 0.89 CHRM4 (0.36) LMNAMAPTOPRM1OPRD1BRD4
SCHEMBL24469913 0.88 OPRM1 (0.33) OPRM1OPRL1USP7CREBBP
SCHEMBL24469763 0.87 USP7 (0.33) USP7
SCHEMBL24484130 0.87 CCNC (0.32) CRBNUSP7
SCHEMBL24470105 0.87 USP7 (0.33) USP7
SCHEMBL24469835 0.85 CRBN (0.39) CRBNLMNAMAPK11MAPK14BRD4
Trifluoroacetic Acid SCHEMBL29670456 0.85 CHRM4 (0.35)
Trifluoroacetic Acid SCHEMBL29670394 0.84 OPRM1 (0.32) OPRM1OPRL1
Trifluoroacetic Acid SCHEMBL29670376 0.84 F11 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820773-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-11820773-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
WO-2022115384-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2022-06-02 WO disclosed
US-20220169650-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169650-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL CRBN 4086/4885LMNA 1680/4885MAPT 651/4885
US-11820773-B2 Tricyclic compounds SLC10A1, PKD1, CEL CRBN 4086/4885LMNA 1680/4885MAPT 651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.